61.9 F
Elizabeth City
Wednesday, April 21, 2021

India extends shelf life of Serum’s Covishield to 9 months: Report

Must read

India’s drug regulator has allowed the AstraZeneca Covid-19 vaccine to be used for up to nine months from its manufacture date, as opposed to the prescribed six months, according to a document reviewed by Reuters and a source.

The approval, given to a licensed version of the drug made by the Serum Institute of India (SII) and exported to dozens of countries, could help health authorities minimise vaccine wastage and better plan their inoculation programmes.

Some African countries have only until the middle of next month to use up more than a million doses of the vaccine – branded Covishield by SII – if the shelf life is not extended.

“You are permitted to apply the shelf-life of 9 month to unlabelled vials available on hand,” India’s drugs controller-general, V.G. Somani, wrote late last month in reply to a request from the SII.

AstraZeneca said in a statement last week that its product could be stored, transported and handled at normal refrigerated conditions for at least six months. The World Health Organization website also gives the shelf-life of Covishield and the South Korean-made AstraZeneca shot as six months.

Reuters has reviewed Somani’s approval, which has been communicated to some African countries, but could not determine if his recommendation applied to unused vials. Each vial typically contains 5 millilitre of vaccine, or 10 doses.

The source, with direct knowledge of the matter but not authorised to discuss it publicly, said the approval was given based on data submitted by the SII. The source did not specify what kind of data was shared by the company, the world’s biggest vaccine maker.

Somani, the SII and AstraZeneca did not immediately respond to requests for comment.

India has so far administered 55 million Covishield doses at home and exported nearly 64 million. India is also using another vaccine developed domestically by Bharat Biotech.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.


We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read More

- Advertisement -

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisement -

Latest article